---
document_datetime: 2025-12-02 06:11:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi.html
document_name: docetaxel-kabi.html
version: success
processing_time: 0.108284
conversion_datetime: 2025-12-24 00:37:57.938864
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Docetaxel Kabi

[RSS](/en/individual-human-medicine.xml/67107)

##### Authorised

This medicine is authorised for use in the European Union

docetaxel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Docetaxel Kabi](#news-on)
- [More information on Docetaxel Kabi](#more-information-on-docetaxel-kabi-1537)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Docetaxel Kabi is a cancer medicine used to treat the following types of cancer:

- breast cancer. Docetaxel Kabi can be used on its own after other treatments have failed. It can also be used with other cancer medicines (capecitabine, cyclophosphamide, doxorubicin or trastuzumab) in patients who have not yet received treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
- non-small-cell lung cancer. Docetaxel Kabi can be used on its own after other treatments have failed. It can also be used with cisplatin (another cancer medicine) in patients who have not yet received any treatment for their cancer;
- prostate cancer that has spread to other parts of the body (metastatic). Docetaxel Kabi is used with androgen-deprivation therapy (therapy greatly reducing the body's production of testosterone) when such treatment still works. Docetaxel Kabi is used with prednisone or prednisolone (anti-inflammatory medicines) when the cancer is castration resistant (androgen-deprivation therapy does not work);
- metastatic gastric adenocarcinoma (a stomach cancer) in patients who have not yet received any treatment for metastatic cancer. Docetaxel Kabi is used with cisplatin and fluorouracil (other cancer medicines);
- head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). Docetaxel Kabi is used with cisplatin and fluorouracil.

Docetaxel Kabi is a 'generic medicine'. This means that Docetaxel Kabi is similar to a 'reference medicine' already authorised in the European Union (EU) called Taxotere.

Docetaxel Kabi contains the active substance docetaxel.

Expand section

Collapse section

## How is Docetaxel Kabi used?

Docetaxel Kabi can only be obtained with a prescription and should only be used in units specialising in giving chemotherapy (medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.

Docetaxel Kabi is given as a 1-hour infusion every 3 weeks. The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated and the patient's weight and height. An anti?inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Docetaxel Kabi infusion. The dose of Docetaxel Kabi may need to be reduced, or treatment interrupted or discontinued, if the patient develops certain side effects.

For more information about using Docetaxel Kabi, see the package leaflet or contact your doctor or pharmacist.

## How does Docetaxel Kabi work?

The active substance in Docetaxel Kabi, docetaxel, belongs to the group of cancer medicines known as taxanes. Docetaxel blocks the ability of cells to break down the internal 'skeleton' that allows them to divide. With the skeleton still in place, the cells cannot divide and they eventually die. Because docetaxel works on dividing cells, it affects non?cancer cells such as blood cells, which can cause side effects.

## How has Docetaxel Kabi been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Taxotere, and do not need to be repeated for Docetaxel Kabi.

As for every medicine, the company provided studies on the quality of Docetaxel Kabi. There was no need for 'bioequivalence' studies to investigate whether Docetaxel Kabi is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Docetaxel Kabi is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Docetaxel Kabi?

Because Docetaxel Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Docetaxel Kabi authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Docetaxel Kabi has been shown to be comparable to Taxotere. Therefore, the Agency's view was that, as for Taxotere, the benefits of Docetaxel Kabi outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Docetaxel Kabi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Docetaxel Kabi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Docetaxel Kabi are continuously monitored. Side effects reported with Docetaxel Kabi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Docetaxel Kabi

Docetaxel Kabi received a marketing authorisation valid throughout the EU on 22 May 2012.

Docetaxel Kabi : EPAR - Summary for the public

Reference Number: EMA/271756/2020

English (EN) (145.07 KB - PDF)

**First published:** 18/06/2012

**Last updated:** 19/05/2020

[View](/en/documents/overview/docetaxel-kabi-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-60)

български (BG) (167.49 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/bg/documents/overview/docetaxel-kabi-epar-summary-public_bg.pdf)

español (ES) (145.33 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/es/documents/overview/docetaxel-kabi-epar-summary-public_es.pdf)

čeština (CS) (166.6 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/cs/documents/overview/docetaxel-kabi-epar-summary-public_cs.pdf)

dansk (DA) (144.42 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/da/documents/overview/docetaxel-kabi-epar-summary-public_da.pdf)

Deutsch (DE) (148.02 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/de/documents/overview/docetaxel-kabi-epar-summary-public_de.pdf)

eesti keel (ET) (132.7 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/et/documents/overview/docetaxel-kabi-epar-summary-public_et.pdf)

ελληνικά (EL) (167.42 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/el/documents/overview/docetaxel-kabi-epar-summary-public_el.pdf)

français (FR) (146.03 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/fr/documents/overview/docetaxel-kabi-epar-summary-public_fr.pdf)

hrvatski (HR) (164.72 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/hr/documents/overview/docetaxel-kabi-epar-summary-public_hr.pdf)

italiano (IT) (143.97 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/it/documents/overview/docetaxel-kabi-epar-summary-public_it.pdf)

latviešu valoda (LV) (173.97 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/lv/documents/overview/docetaxel-kabi-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (165.23 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/lt/documents/overview/docetaxel-kabi-epar-summary-public_lt.pdf)

magyar (HU) (167.42 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/hu/documents/overview/docetaxel-kabi-epar-summary-public_hu.pdf)

Malti (MT) (166.2 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/mt/documents/overview/docetaxel-kabi-epar-summary-public_mt.pdf)

Nederlands (NL) (144.69 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/nl/documents/overview/docetaxel-kabi-epar-summary-public_nl.pdf)

polski (PL) (168.36 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/pl/documents/overview/docetaxel-kabi-epar-summary-public_pl.pdf)

português (PT) (145.83 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/pt/documents/overview/docetaxel-kabi-epar-summary-public_pt.pdf)

română (RO) (165.41 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/ro/documents/overview/docetaxel-kabi-epar-summary-public_ro.pdf)

slovenčina (SK) (167.01 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/sk/documents/overview/docetaxel-kabi-epar-summary-public_sk.pdf)

slovenščina (SL) (163.69 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/sl/documents/overview/docetaxel-kabi-epar-summary-public_sl.pdf)

Suomi (FI) (142.6 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/fi/documents/overview/docetaxel-kabi-epar-summary-public_fi.pdf)

svenska (SV) (143.7 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

19/05/2020

[View](/sv/documents/overview/docetaxel-kabi-epar-summary-public_sv.pdf)

## Product information

Docetaxel Kabi : EPAR - Product Information

English (EN) (2.48 MB - PDF)

**First published:** 18/06/2012

**Last updated:** 04/08/2025

[View](/en/documents/product-information/docetaxel-kabi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-819)

български (BG) (3.4 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/bg/documents/product-information/docetaxel-kabi-epar-product-information_bg.pdf)

español (ES) (2.46 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/es/documents/product-information/docetaxel-kabi-epar-product-information_es.pdf)

čeština (CS) (1.17 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/cs/documents/product-information/docetaxel-kabi-epar-product-information_cs.pdf)

dansk (DA) (2.84 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/da/documents/product-information/docetaxel-kabi-epar-product-information_da.pdf)

Deutsch (DE) (3.24 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/de/documents/product-information/docetaxel-kabi-epar-product-information_de.pdf)

eesti keel (ET) (2.34 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/et/documents/product-information/docetaxel-kabi-epar-product-information_et.pdf)

ελληνικά (EL) (3.32 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/el/documents/product-information/docetaxel-kabi-epar-product-information_el.pdf)

français (FR) (2.37 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/fr/documents/product-information/docetaxel-kabi-epar-product-information_fr.pdf)

hrvatski (HR) (2.66 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/hr/documents/product-information/docetaxel-kabi-epar-product-information_hr.pdf)

íslenska (IS) (2.34 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/is/documents/product-information/docetaxel-kabi-epar-product-information_is.pdf)

italiano (IT) (2.42 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/it/documents/product-information/docetaxel-kabi-epar-product-information_it.pdf)

latviešu valoda (LV) (2.7 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/lv/documents/product-information/docetaxel-kabi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.77 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/lt/documents/product-information/docetaxel-kabi-epar-product-information_lt.pdf)

magyar (HU) (2.88 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/hu/documents/product-information/docetaxel-kabi-epar-product-information_hu.pdf)

Malti (MT) (3.01 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/mt/documents/product-information/docetaxel-kabi-epar-product-information_mt.pdf)

Nederlands (NL) (2.58 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/nl/documents/product-information/docetaxel-kabi-epar-product-information_nl.pdf)

norsk (NO) (2.47 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/no/documents/product-information/docetaxel-kabi-epar-product-information_no.pdf)

polski (PL) (2.76 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/pl/documents/product-information/docetaxel-kabi-epar-product-information_pl.pdf)

português (PT) (2.51 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/pt/documents/product-information/docetaxel-kabi-epar-product-information_pt.pdf)

română (RO) (3.02 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/ro/documents/product-information/docetaxel-kabi-epar-product-information_ro.pdf)

slovenčina (SK) (2.87 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/sk/documents/product-information/docetaxel-kabi-epar-product-information_sk.pdf)

slovenščina (SL) (2.68 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/sl/documents/product-information/docetaxel-kabi-epar-product-information_sl.pdf)

Suomi (FI) (2.54 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/fi/documents/product-information/docetaxel-kabi-epar-product-information_fi.pdf)

svenska (SV) (2.26 MB - PDF)

**First published:**

18/06/2012

**Last updated:**

04/08/2025

[View](/sv/documents/product-information/docetaxel-kabi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000282406 04/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Docetaxel Kabi : EPAR - All Authorised presentations

English (EN) (22.03 KB - PDF)

**First published:** 18/06/2012

**Last updated:** 27/11/2012

[View](/en/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-729)

български (BG) (53.08 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/bg/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.94 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/es/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.14 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/cs/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.55 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/da/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.6 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/de/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.69 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/et/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.98 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/el/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_el.pdf)

français (FR) (18.87 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/fr/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (18.8 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/is/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.76 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/it/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.37 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/lv/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.63 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/lt/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.57 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/hu/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.98 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/mt/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (19 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/nl/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.73 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/no/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.24 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/pl/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.79 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/pt/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.97 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/ro/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.95 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/sk/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.69 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/sl/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.7 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/fi/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.72 KB - PDF)

**First published:**

18/06/2012

**Last updated:**

27/11/2012

[View](/sv/documents/all-authorised-presentations/docetaxel-kabi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Docetaxel Kabi Active substance docetaxel International non-proprietary name (INN) or common name docetaxel Therapeutic area (MeSH)

- Head and Neck Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Prostatic Neoplasms
- Breast Neoplasms

Anatomical therapeutic chemical (ATC) code L01CD02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Breast cancer**

Docetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

- operable node-positive breast cancer;
- operable node-negative breast cancer.

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.

Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.

Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

**Non-small-cell lung cancer**

Docetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

**Prostate cancer**

Docetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.

Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.

**Gastric adenocarcinoma**

Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

**Head and neck cancer**

Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

## Authorisation details

EMA product number EMEA/H/C/002325

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Fresenius Kabi Deutschland GmbH

Else-Kröner-Straße 1,

Opinion adopted 15/03/2012 Marketing authorisation issued 22/05/2012 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Docetaxel Kabi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.93 KB - PDF)

**First published:** 04/08/2025

[View](/en/documents/procedural-steps-after/docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Docetaxel Kabi : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (154.76 KB - PDF)

**First published:** 27/11/2012

**Last updated:** 29/09/2023

[View](/en/documents/procedural-steps-after/docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

## Initial marketing authorisation documents

Docetaxel Kabi : EPAR - Public assessment report

Reference Number: EMA/305675/2012

English (EN) (125.35 KB - PDF)

**First published:** 18/06/2012

**Last updated:** 18/06/2012

[View](/en/documents/assessment-report/docetaxel-kabi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Docetaxel Kabi

Adopted

Reference Number: EMA/CHMP/56643/2012

English (EN) (62.86 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 16/03/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-kabi_en.pdf)

#### News on Docetaxel Kabi

[PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel](/en/news/prac-concludes-there-no-evidence-change-known-risk-neutropenic-enterocolitis-docetaxel) 09/06/2017

#### More information on Docetaxel Kabi

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/08/2025

## Share this page

[Back to top](#main-content)